Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06299761 · ClinicalTrials.gov registry record · Phase 1
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
A Phase 1 study, sponsored by Boundless Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT06299761: Clinical Trial Phase 1 study, sponsored by Boundless Bio.
NCT06299761 is a Phase 1 study that was terminated before completion, run by Boundless Bio. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06299761, a Phase 1 study, was terminated before completion, sponsored by Boundless Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-825 administered as a single agent and in combination with select targeted therapies.
Primary Outcome
TEAEs will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Interventions
- DRUG BBI-825
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 1 |
Why NCT06299761 stopped before completion
NCT06299761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which BBI-825 is the first listed.
NCT06299761 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06299761 about?
NCT06299761 is a clinical study titled "Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications". BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-825 administered...
What is the current status of trial NCT06299761?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2024-03-28. Estimated completion is 2025-06-25.
What interventions are being tested in trial NCT06299761?
The interventions under investigation include: BBI-825 (DRUG).
Who is sponsoring clinical trial NCT06299761?
This trial is sponsored by Boundless Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06299761's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI